BrainGate
BrainGate is a multi-institutional research consortium developing an investigational intracortical brain-computer interface that decodes intended movement and speech from the motor cortex to restore communication and mobility for people with paralysis, ALS, and locked-in syndrome.
- Company typePrivate
- Founded2000
- HeadquartersStanford, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What BrainGate does
BrainGate is a multi-institutional research consortium developing an intracortical brain-computer interface (iBCI) to restore communication, mobility, and independence for people affected by paralysis, ALS, brainstem stroke, muscular dystrophy, and other neurologic conditions. The core platform is the investigational BrainGate2 Neural Interface System, which uses implanted microelectrode arrays in the motor cortex to record neural activity and decode intended movements and speech via machine learning algorithms (LSTM-based decoders, RNNs for bimanual control). On top of this platform, the consortium has built specialized products including a Speech Neuroprosthesis (99% word accuracy, 56 WPM in independent home use), a Handwriting BCI, an instantaneous Voice-Synthesis Neuroprosthesis (Nature 2025), a Movement Restoration BCI using functional electrical stimulation, and an Assistive Communication cursor/keyboard system.
The consortium is led by Dr. Leigh Hochberg (Director) and brings together Massachusetts General Hospital, Brown University, Stanford, UC Davis, Emory, the VA Providence Healthcare System, Baylor College of Medicine (joined May 2026), and Rice University (joined May 2026), with Dr. John Donoghue as a foundational figure. The go-to-market is exclusively clinical-trial-based: six U.S. investigational sites recruit participants with tetraplegia who live within a three-hour drive, for a 13-month study commitment. There is no commercial revenue; the device is investigational and provided at no cost, with operations funded by NIH, VA RR&D, DARPA, and private foundations. The consortium has produced 200+ peer-reviewed publications since 1995, including first-in-human demonstrations of high-bandwidth wireless iBCI, intracortical handwriting decoding, and 3,800+ hours of independent at-home use by an ALS participant.
BrainGate firmographics
Firmographics- Name
- BrainGate
- Legal name
- BrainGate
- Website
- https://braingate.org
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BrainGate is a multi-institutional research consortium developing an investigational intracortical brain-computer interface that decodes intended movement and speech from the motor cortex to restore communication and mobility for people with paralysis, ALS, and locked-in syndrome.
- Ownership category
- akta.pro rank
BrainGate industry classification
Industry- Product category
- Neural Implants
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)
Keywords
Where BrainGate is headquartered
LocationHeadquarters
- HQ city
- Stanford
- HQ country
- United States
- HQ region
- North America
Markets served
BrainGate business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Research funding and grants: BrainGate is a research consortium funded primarily through grants from government agencies (NIH, NSF, VA, DARPA), foundations (ALS Association, American Heart Association, Craig H. Neilsen Foundation, Doris Duke Charitable Foundation), and philanthropy. No commercial revenue is generated as the device remains investigational.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Investigational device - not commercially available |
Distribution channels1 record
Marketing channels4 records
BrainGate product offering
Product offeringCore offering
BrainGate is a research consortium developing and clinically testing the investigational BrainGate2 Neural Interface System, an intracortical brain-computer interface that records neural activity from microelectrode arrays implanted in the motor cortex. The system decodes intended movements and speech using machine learning algorithms, powering specialized applications such as speech neuroprostheses, voice-synthesis neuroprostheses, handwriting BCIs, movement restoration via FES, and assistive cursor/keyboard control for people with paralysis. All offerings are limited by federal law to investigational use and are provided to clinical trial participants at no cost.
Product overview
BrainGate is an investigational brain-computer interface technology consortium developing multiple interconnected BCI products for people with paralysis and neurologic disease. The core offering is the BrainGate2 Neural Interface System, an intracortical microelectrode array that records neural signals to decode intended movements and speech. This platform powers several specialized applications: the Speech Neuroprosthesis for communication restoration, the Handwriting BCI and Voice Synthesis Neuroprosthesis for rapid text and voice output, the Movement Restoration BCI for limb control via FES, and the Assistive Communication BCI for cursor control. All products are investigational devices limited by federal law to clinical research use only.
Differentiator
Problem solved
Functional benefit
Brands
- BrainGate2: The second-generation BrainGate neural interface system used in ongoing clinical trials
Products and services
- BrainGate2 Neural Interface System Investigational intracortical brain-computer interface (iBCI) that records neural signals from microelectrode arrays implanted in the motor cortex, decoding intended movements and speech so people with paralysis can control computers, prosthetic limbs, and communication devices with their thoughts.
- Speech Neuroprosthesis BCI system that decodes neural signals responsible for speech production directly from the cortex, converting attempted speech into text or synthesized voice to restore fluent conversational communication for people with ALS, brainstem stroke, and anarthria.
- Voice Synthesis Neuroprosthesis Real-time voice synthesis system that converts neural signals into synthesized speech during attempted vocalized speech, providing auditory feedback to the user alongside text decoding.
- Handwriting Brain-Computer Interface BCI system that decodes imagined handwriting movements from neural signals to enable rapid text entry, achieving typing speeds more than twice as fast as traditional point-and-click BCI typing methods.
- Movement Restoration BCI Neuroprosthetic system that decodes intended movement signals from the motor cortex and sends commands to muscles via implanted stimulating electrodes (FES) to induce limb movement, restoring motor function for people with cervical spinal cord injury or brainstem stroke.
- Assistive Communication BCI Cursor and keyboard control system enabling people with locked-in syndrome to control computers and communicate by thinking about hand movements, as if controlling a computer mouse, without muscular movement.
Quantifiable outcome
- 99% word accuracy in speech decoding during independent home use
- +4 more outcomes
Companies that use BrainGate
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles2 records
BrainGate technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature8 records
BrainGate partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Massachusetts General Hospital (MGH)corePrimary institutional partner and sponsor-investigator site. Dr. Leigh Hochberg serves as Director of BrainGate Consortium and Clinical Trials from MGH. The Center for Neurotechnology and Neurorecovery (CNTR) is based at MGH.
- Brown UniversitycoreHome institution of Dr. John Donoghue (founder) and Dr. Leigh Hochberg. Robert J. & Nancy D. Carney Institute for Brain Science collaborates on neural interface research. Dr. Hochberg holds position as Professor of Engineering at Brown.
- Stanford UniversitycoreClinical trial site led by Dr. Jaimie Henderson. Stanford Neural Prosthetics Translational Laboratory (NPTL) co-develops BCI technology. Stanford joined as clinical site in 2011.
- University of California, DaviscoreClinical trial site and key research partner. UC Davis Neuroprosthetics Lab co-directed by Dr. David Brandman. Rice University and Baylor College of Medicine joined the consortium in May 2026.
- Emory UniversitycoreClinical trial site led by Dr. Nicholas Au Yong, Associate Professor of Neurosurgery and Biomedical Engineering.
- VA Providence Healthcare SystemcoreVA RR&D Center for Neurorestoration and Neurotechnology directed by Dr. Leigh Hochberg. Clinical trial site with Dr. Stephen Mernoff as co-investigator.
- Baylor College of MedicinecoreMost recently added consortium partner in May 2026. Dr. Sameer Sheth serves as Principal Investigator, bringing expertise in cognitive neurophysiology and psychiatric neurosurgery.
- Rice UniversitycoreJoined consortium in May 2026. Neuroengineering Initiative and Rice Brain Computer Interface Lab collaborate on neural interface research.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
BrainGate competitors and assessment
Company assessmentDirect peers
- Synchron: Synchron develops the Stentrode, an endovascular brain-computer interface delivered through blood vessels, avoiding open brain surgery. It targets the same locked-in syndrome and paralysis patient population as BrainGate but with a fundamentally less invasive delivery mechanism and earlier commercial milestones.
- Neuralink: Neuralink develops implantable brain-computer interfaces using high-channel-count electrode arrays, targeting similar applications in motor control and speech restoration for paralysis patients. It is the most prominent direct competitor to BrainGate in the iBCI space, with significant private capital and a high-profile public profile.
- Precision Neuroscience: Precision Neuroscience is developing a minimally invasive cortical interface using a thin-film electrode array that sits on the brain surface. It targets motor and speech restoration applications overlapping with BrainGate, with a less invasive surgical approach.
- Paradromics: Paradromics is developing high-data-rate intracortical BCIs using novel electrode architectures for both medical and future consumer applications. It targets similar neural decoding use cases as BrainGate's motor cortex recordings and represents another well-funded iBCI competitor.
- Blackrock Neurotech: Blackrock Neurotech provides the Utah array hardware used in BrainGate's clinical trials and independently develops its own BCI systems for paralysis and communication restoration. It is both a technology supplier to BrainGate and a direct competitor pursuing commercial BCI deployment.
Emerging players
- Inbrain Neuroelectronics: Inbrain Neuroelectronics develops graphene-based neural interfaces for both decoding and stimulation applications in neurological disorders. It targets similar clinical indications as BrainGate (speech, motor restoration) with differentiated electrode materials.
- Motif Neurotech: Motif Neurotech is developing minimally invasive brain stimulation implants for psychiatric and neurological disorders. While focused more on therapeutics than communication BCIs, it represents an emerging player in the implantable neurotechnology space with adjacent technology.
Broad incumbents
- NeuroPace: NeuroPace is an established commercial neurotechnology company with FDA-approved responsive neurostimulation for epilepsy. It operates broadly in implantable neurological devices, overlapping with BrainGate's neurotherapeutics research area but not directly competing in speech/motor BCIs.
- Medtronic: Medtronic is a major medical device company with extensive neurological and brain stimulation products (deep brain stimulation, spinal cord stimulation). It serves as a broad incumbent in neurotechnology with the resources to enter the BCI market through acquisition or internal development.
- Abbott (Neuromodulation): Abbott's Neuromodulation division produces deep brain stimulation and spinal cord stimulation devices for neurological disorders. As a major incumbent in implantable neurotechnology, it represents a potential strategic acquirer or competitor with the scale to commercialize BCI technology globally.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BrainGate social profiles
Digital presenceBrainGate financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainGate leadership team
Management profileNumber of profiles
Profiles8 records
BrainGate funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainGate M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainGate
What does BrainGate do?
BrainGate is a research consortium developing and clinically testing the investigational BrainGate2 Neural Interface System, an intracortical brain-computer interface that records neural activity from microelectrode arrays implanted in the motor cortex. The system decodes intended movements and speech using machine learning algorithms, powering specialized applications such as speech neuroprostheses, voice-synthesis neuroprostheses, handwriting BCIs, movement restoration via FES, and assistive cursor/keyboard control for people with paralysis. All offerings are limited by federal law to investigational use and are provided to clinical trial participants at no cost.
Is BrainGate a public or private company?
BrainGate is a private company. It is classified as unknown and is currently operating.
When was BrainGate founded?
BrainGate was founded in 2000. It employs 51 to 100 people.
Where is BrainGate based?
BrainGate is headquartered in Stanford, United States, in the North America region.
How does BrainGate make money?
One revenue line is on record: research funding and grants.
Who are BrainGate's main competitors?
Direct peers on record are Synchron, Neuralink, Precision Neuroscience, Paradromics and Blackrock Neurotech. Emerging players are Inbrain Neuroelectronics and Motif Neurotech. Broad incumbents are NeuroPace, Medtronic and Abbott (Neuromodulation).
Does BrainGate have an API?
No public API is recorded for BrainGate.
What industry is BrainGate in?
BrainGate's product category is Neural Implants. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 5417 and its SIC code is 8731.